natgillin/translations-raw huggingface dataset:
Where the emulsion is dried, e.g. by lyophilization, the discontinuous nature of the oil phase is maintained even though the water content of the emulsion residue may be extremely low. 
Oralno primjenjiv pripravak za žvakanje u obliku jedinične doze koji sadrži ulje-u-vodi emulziju gdje je vodena faza gelirana 1 gdje uljna faza obuhvaća riblje ulje, pri čemu je težina te jedinične doze 0.25-3g.
The first curved surface 18 of the control means 13 . 
(33) Država ili organizacija podnošenja prve prijave: FR
The method of claim 6, wherein the mixed mode ion exchange material is an ion exchange material comprising a mixture of sequentially packed sulfonated chromatography material or carboxylated chromatography material and a quaternary amine chromatography material or tertiary amine chromatography material. 
Postupak prema patentnom zahtjevu 7, naznačen time, da je materijal ionske izmjene mješovitog načina rada smjesa sekvencijalno pakiranog materijala sulfoniranog kromatografskog materijala ili karboksiliranog kromatografskog materijala i kromatografskog materijala kvarternog amina ili kromatografskog materijala tercijarnog amina.
A solution for wood preservation, comprising ethanolamine, copper (II) sulphate pent-hydrate, disodium octaborate tetrahydrate, alkylbenzyldimethyl ammonium chloride, and octanoic acid dissolved in water, wherein 1000 g of aqueous preservative solution comprises 57.69 g ethanolamine, 39.32 g copper (II) sulphate pent-hydrate, 8.1 g disodium octaborate tetrahydrate, 10.8 g alkylbenzyldimethyl ammonium chloride, and 11.35 g octanoic acid dissolved in water. 
Otopina za konzerviranje drva prema zahtjevu 10, u kojoj se 1000 g vodene otopine konzervansa sastoji od 57,69 g etanolamina, 39,32 g bakar (II) sulfat penta-hidrata, 8,1 g natrij oktaborat tetrahidrata, 10,8 g alkilbenzildimetil amonij klorida i 11,35 g oktanoične kiseline.
The clear solution obtained in this way is sterilized by filtration and bottled under aseptic conditions. 
Na ovaj način dobivena bistra otopina se sterilizira filtrirajem i puni se u bočice uz aseptičke uvjete.
The mixture of polypeptides of the invention (mg) 
(97) Broj objave europskog patenta:
% to 30 % weight: weight Teriflunomide, or a pharmaceutically acceptable basic addition salt thereof, 
% do 30 % težinski: težinski Teriflunomida, ili njegove farmaceutski prihvatljive bazične adicijske soli,
As used herein, the term “alkyl” denotes branched or unbranched hydrocarbon chains containing 1 to 20 carbons, preferably 1 to 12 carbons, and more preferably 1 to 8 carbons, in the normal chain, such as, methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl and the like. 
Kao što se ovdje upotrebljava, termin "alkil" označava razgranate ili nerazgranate ugljikovodične lance koji sadrže 1 do 20 ugljika, poželjnije 1 do 12 ugljika i još poželjnije 1 do 8 ugljika, u uobičajenim lancima kao što su metil, etil, propil, izopropil, butil, sec-butil, izo-butil, terc-butil, pentil, heksil, izoheksil, heptil, 4,4-dimetilpentil, oktil, 2,2,4-trimetipentil i slično.
The anti-FOLR1 antibody or anti-FOLR1 immunoconjugate for use of claim 13, wherein the linker of the anti-FOLR1 immunoconjugate is N-succinimidyl 4-(2-pyridyldithio)-2 sulfobutanoate (sulfo-SPDB) . 
Protutijelo protiv FOLRI ili imunokonjugat protiv FOLR1, namijenjeni upotrebi u skladu s patentnim zahtjevom 13, naznačeni time što je spojnica za imunokonjugat protiv FOLR1 N-sukcinimidil-4-(2-piridilditio)-2- sulfobutanoat (sulfo-SPDB).
Methods according to claim 14, characterised in that the immunoglobulin comprises any of the loop regions of Ig-kappa or Ig-lambda comprising a modifications in one of the amino acid positions within the amino acid sequence selected from the group consisting of amino acids 8 to 18, amino acids 27 to 35, amino acids 42 to 70, amino acids 83 to 85, amino acids 92 to 100, amino acids 108 to 117 and amino acids 123 to 126, wherein the numbering is According to IMGT. 
Postupak u skladu sa zahtjevom 14, naznačen time, da imunoglobulin obuhvaća neko od područja petlje Ig-kapa ili 1g-lambda koja obuhvaćaju modifikaciju u jednom aminokiselinskom položaju unutar aminokiselinske sekvence izabrane iz skupine koju čine aminokiseline 8 do 18, aminokiseline 27 do 35, aminokiseline 42 do 70, aminokiseline 83 do 85, aminokiseline 92 do 100, aminokiseline 108 do 117 i aminokiseline 123 do 126, pri čemu je numeriranje prema IMGT.
IL-18BP has been suggested as a therapeutic protein in a number of diseases and disorders, such as psoriasis, Crohn's Disease, rheumatoid arthritis, psoriatic arthritis, liver injury, sepsis, atherosclerosis, ischemic heart diseases, allergies, etc., e.g. disclosed in WO9909063, WO0107480, WO0162285, WO0185201, WO02060479, WO02096456, WO03080104, WO02092008, WO02101049, WO03013577. 
IL-18BP je predložen kao terapeutski protein u brojnim bolestima i poremećajima, primjerice psorijazi, Crohnovoj bolesti, reumatoidnom artritisu, psorijatičnim artritisu, pri ozljedama jetre, sepsi, aterosklerozi, ishemičnoj bolesti srca, alergijama itd., primjeri navedeni u WO9909063, WO0107480, WO0162285, WO0185201, WO02060479, WO02096456, WO03080104, WO02092008, WO02101049, WO03013577.
Use of the thymosin alpha 1, for preparing a medicament for the prevention and/or treatment of herpes virus diseases in a mammal subject. 
Uporaba tiomiozina alfa 1, naznačena time da je za pripravu medikamenta za prevenciju i/ili liječenje bolesti herpes virusa kod subjekta sisavca.
The method for treating asthma according to claim 2, wherein the anti-human TSLP receptor antibody is an antibody comprising a heavy chain consisting of the amino acid sequence shown by SEQ ID NO: 1, wherein glutamic acid of the amino acid number 1 of SEQ ID NO: 1 is modified to pyroglutamic acid and/or lysine of the amino acid number 448 of SEQ ID NO: 1 is deleted, and a light chain consisting of the amino acid sequence shown by SEQ ID NO: 3. 
Protutijelo protiv ljudskog receptora TSLP u skladu s patentnim zahtjevom 1, naznačeno time što sadrži teški lanac koji se sastoji od aminokiselinskog slijeda kojeg prikazuje SEQ ID NO: 1, u kojem je glutaminska kiselina s aminokiselinskim brojem 1 u SEQ ID NO: 1 modificirana u piroglutaminsku kiselinu i/ili je lizin s aminokiselinskim brojem 448 u SEQ ID NO: 1 izbačen, a laki lanac se sastoji od aminokiselinskog slijeda kojeg prikazuje SEQ ID NO: 3.
cutting the sheet to obtain a blank, then 
- rezanja navedenog lima da bi se dobio radni komad, zatim od
a substitution of the amino acid residue at position 355, according to the EU numbering system, by a negatively charged amino acid residue; 
druge molekule nukleinske kiseline koja kodira drugi polipeptidni lanac koji sadrži CH3 domenu humanog IgG, koji sadrži ostatak asparaginske kiseline (D) na aminokiselinskom položaju 351 u skladu s EU sustavu numeracije,
After hardening of the polymer, the surface of the resulting magnetic body carries the indicia transferred by the form. 
Nakon otvrdnjavanja polimera, površina dobivenog magnetskog tijela nosi oznaku koja se prenosi navedenim oblikom.
The New Methylene Blue can be present in amounts sufficient to result in concentrations of about 70 uM to about 2.4 mM under staining conditions. 
Novo metilensko modrilo je prisutno u dovoljnoj količini da se dobiju koncentracije od oko 70 uM do oko 2.4 MM u uvjetima bojenja; i
Preferably, the amount of rapamycin is about 80 to about 180 mg/m2 (e.g ., about 100 mg/m2 to about 150 mg/m2, such as about 120 mg/m2). 
Pripravak koji sadrži nanočestice koje sadrže rapamicin i protein nosač, za upotrebu u postupku liječenja raka kod čovjeka, naznačen time što je količina rapamicina u rasponu od 25 mg/m* do 100 mg/m', ili pri čemu je količina rapamicina u rasponu od 50 mg do 175 mg.
The retinal derivative for use according to Claim 1, wherein the derivative is a 9- cis- retinyl ester of a C1 to C10 monocarboxylate. 
Derivat retinala za upotrebu u skladu s patentnim zahtjevom 2, naznačen time, da je to 9-cis-retinil ester C3-C22 polikarboksilata.
Wind system (1) according to claim 7, characterised in that said permanent magnets are neodymium iron boron magnets. 
Vjetreni sustav (1) prema zahtjevu 9, naznačen time da se prilikom manevra bočnog klizanja spomenuti bočni izbojci podignu pod djelovanjem protoka.
a light chain variable region comprising the CDRs of SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 wherein said antibody is capable of competing with the murine B-Ly1 antibody for binding to CD20 and comprises a glycoengineered human Fc region, wherein said Fc region has been glycoengineered in a host cell engineered to express at least one nucleic acid sequence encoding a polypeptide having B(1,4)-N-acetylglucosaminyltransferase III activity 
varijabilno područje lakog lanca koje obuhvaća CDR područja od SEQ ID NO:18, SEQ ID NO: 19 i SEQ ID NO: 20, pri čemu je protutijelo sposobno za natjecanje s mišjim protutijelom B-Ly1 za vezanje na CD20 te obuhvaća ljudsko Fc područje podvrgnuto glikoinženjeringu, gdje je navedeno Fc područje bilo podvrgnuto glikoinženjeringu u stanici domaćina koja je konstruirana za ekspresiju najmanje jedne sekvence nukleinske kiseline koja kodira polipeptid s djelovanjem B(1,4)-N-acetilglukozaminiltransferaze III,
8, or of an amino acid sequence having at least 75% identity, preferably 80% identity, most preferably 90 % identity, most highly preferably 95 % identity to SEQ ID NO. 
8, ili sekvence aminokiselina koji ima barem 75% identičnosti, poželjno 80% identičnosti, još poželjnije 90% identičnosti, najpoželjnije 95% identičnosti sa SEQ ID br.
Embodiment 52 The pharmaceutical composition of any preceding embodiment wherein the crosslinked amine polymer has a proton binding capacity of at least 10 mmol/g and a chloride ion binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer (“SGF”) containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37° C. 
Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, gdje je umreženi aminski polimer sa kapacitetom vezanja protona od najmanje 10 mmol/g i kapacitetom vezanja kloridnih iona od najmanje 10 mmol/g, u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCI 1 63 mM ECI, pri pH 1,21 na 3TC.
The process according to claim 2, wherein for the preparation of the intermediate boronic acid compound or borolane reagent, the reagents palladium acetate, triethylamine and triphenylphosphine or PdCl2(PPh3)2 and triethylamine are used. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu se za pripremu intermedijernog derivata bronične kiseline ili reagensa borolana koriste reagensi paladij acetat, trietilamin i trifenilfosfin, ili PAC1j(PPhj), i trietilamin.
These complex linkers are designed to self-eliminate via cyclization subsequent to enzymatic removal of the glycosyl moiety. 
Ovi kompleksni veznici dizajnirani su tako da se sami uklanjaju putem ciklizacije nakon enzimskog uklanjanja glikozilne cjeline.
contacting the sample with AB-aggregates and allowing the AB-specific antibodies to bind to the AB-aggregates, and 
stavljanje u doticaj uzorka s Aß-agregatima ili s kuglicama koje imaju Aß-agregate imobilizirane na svojoj površini, te dopuštanje Aß-specifičnim protutijelima da se vežu na Aß-agregate, i
contacting a GPR119 agonist in vitro with a vertebrate enteroendocrine cell or a cell capable of secreting GIP; 
stavljanje u doticaj onoga spoja u čijoj je prisutnosti formirano manje kompleksa u koraku (c) in vitro sa enteroendokrinom stanicom kralježnjaka ili sa stanicom sposobnom za GIP sekreciju; i
The compound for use according to claim 11, wherein said disease or condition is cancer, polycythemia vera, essential thrombocytosis, myelofibrosis, chronic myelogenous leukemia (CML), rheumatoid arthritis, inflammatory bowel syndrome, Crohn's disease, psoriasis, contact dermatitis or delayed hypersensitivity reactions. 
Spoj za uporabu prema zahtjevu 3, naznačen time, da se upotrebljava u prevenciji, liječenju ili smanjivanju težine bolesti ili stanja koja/koje je odabrana/odabrano od sljedećih: rak, policitemija vera, esencijalna trombocitoza, mijelofibroza, kronična mijelogena leukemija (CML), reumatoidni artritis, kronična upalna crijevna bolest, Crohnova bolest, psorijaza, kontaktni dermatitis ili odgođene hipersenzitivne reakcije.
The process according to any one of claims 1 to 9, characterized in that said salt of a C5―C28 fatty acid is a salt of a linear fatty acid if said fatty acid is a C6―C9 fatty acid. 
Postupak prema bilo kojem zahtjevu od 1 do 9, naznačen time da navedena sol Cs - C2xg masne kiseline je sol linearne masne kiseline ako je navedena masna kiselina Cg - Ca masna kiselina.
The compounds can be synthesized, for example, by application or adaptation of the methods described below, or variations thereon as appreciated by the skilled artisan. 
Spojeve se, primjerice, može sintetizirati primjenom ili prilagođavanjem postupaka opisanih niže, ili njihovih varijacija, kao što je to poznato stručnjaku.
filtering at least a part of the resulting suspension S by passing at least a part of the resulting suspension S through a filtering device in order to obtain the aqueous solution comprising at least one earth alkali hydrogen carbonate, 
filtriranje barem dijela dobivene suspenzije S prolaskom barem dijela dobivene suspenzije S kroz uređaj za filtriranje kako bi se dobila vodena otopina koja sadrži barem jedan zemnoalkalijski hidrogenkarbonat, pri čemu vodena otopina koja je dobivena nakon filtriranja ima vrijednost zamućenja manju od 1 NTU i ima koncentraciju kalcija, kao kalcijevog karbonata, od 50 do 650 mg/l,
A preventive or therapeutic agent for transient ischemic attack, diabetic neuropathy, diabetic gangrene, peripheral circulatory disturbance, connective tissue disease, reocclusion / restenosis after percutaneous transluminal coronary angioplasty (PTCA), arteriosclerosis, thrombosis, hypertension, pulmonary hypertension, ischemic disorder, angina, glomerulonephritis, diabetic nephropathy, chronic renal failure, allergy, bronchial asthma, ulcer, pressure ulcer (bedsore), restenosis after coronary intervention such as atherectomy and stent implantation, thrombocytopenia by dialysis, the diseases in which fibrosis of organs or tissues is involved, erectile dysfunction, inflammatory bowel disease, gastritis, gastric ulcer, ischemic ophthalmopathy, sudden hearing loss, avascular necrosis of bone, intestinal damage caused by administration of a non-steroidal anti-inflammatory agent, and symptoms associated with lumbar spinal canal stenosis, comprising the crystal of any one of 1 to 3 as an active ingredient. 
Spoj, naznačen time što je namijenjen upotrebi u liječenju dijabetične neuropatije, dijabetične gangrene, poremećaja perifernog krvotoka, kroničnog začepljenja arterija, povremenog šepanja, tromboze, plućne hipertenzije, infarkta miokarda, angine, glomerulonefritisa, dijabetične nefropatije, kronične insuficijencije bubrega, bronhijalne astme, intersticijske pneumonije (plućne fibroze), skleroderme, kronične opstruktivne plućne bolesti, upalne bolesti crijeva, tubulointersticijskog nefritisa, ili simptoma povezanih s lumbalnom stenozom kralježničnog kanala, gdje je spoj kristal u skladu s patentnim zahtjevom 1. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je sredstvo za liječenje plućne hipertenzije. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je sredstvo za liječenje poremećaja perifernog krvotoka.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an isolated antibody comprising a light chain comprising SEQ ID NO: 44 and a heavy chain comprising SEQ ID NO: 40 or an antibody fragment thereof, wherein the antibody or fragment thereof binds nerve growth factor (NGF). 
NO: 43. Antitijelo ili antigen vezujući fragment istog prema zahtjevu 7, naznačen time da antitijelo obuhvaća laki lanac čiji je slijed SEQ ID NO: 44 i teški lanac čiji je slijed SEQ ID NO: 40.
/ Lyophilisation and specific turbidity 
HR P20070487 T3 4/ Liofilizacija i specifična zamućenost
The method of claim 7, wherein the specified number of base pairs is 300 bp, 200 bp, or 100 bp. 
Postupak prema zahtjevu 7, naznačen time, da specifični broj temeljnih parova je 300 bp, 200 bp ili 100 bp.
In another embodiment, the invention is related to the compounds as described above for use in treatment or prophylaxis of diseases that are related to aging, neurodegenerative diseases, infection, diabetes and other indication in which cell damage is involved. 
(6-hidroksi-2,5,7;8-tetrametikhroman-2-11)(4-(2-hidroksietiDpiperazin-1-yl)metanon, naznačen time, da je u svojem racemičnom ili enantiomernom obliku u svrhu liječenja ili profilakse indikacija vezanih za oštećenje stanica izazvano oksidativnim stresom.
selecting at least two initial paths; and 
odabir (2004) barem dvije početne putanje (302); i
Preparation of Isomer B 
Priprema Izomera B
The liposome of any preceding claim, wherein the RNA is a self-replicating RNA. The liposome of claim 6, wherein the self-replicating RNA molecule encodes (i) a RNA-dependent RNA polymerase which can transcribe RNA from the self-replicating RNA molecule and (ii) an immunogen. 
Liposom u skladu s patentnim zahtjevom 8, naznačen time što samoreplicirajuća molekula RNA kodira (i) RNA-ovisna RNA polimerazu koja može transkribirati RNA iz samoreplicirajuće molekule RNA i (ii) imunogen.
In some circumstances, these extrapolations may merely be based on the weight of the animal model in comparison to another, such as a mammal, preferably a human, however, more often, these extrapolations are not simply based on weight differences, but rather incorporate a variety of factors. 
U nekim okolnostima, te ekstrapolacije mogu biti uglavnom zasnovane na težini životinjskog modela u usporedbi s drugim poput sisavaca, odnosno ljudi, naravno, češće, te ekstrapolacije nisu jednostavno zasnovane na razlikama težine već je potrebno ugraditi različite faktore.
Composition according to any one of claims 1 to 8 comprising at least two groups of coated particles differing in the amount and/or the composition of release modifying material and/or comprising different active agents. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 2 do 5, naznačen time,da obuhvaća najmanje dvije skupine obloženih čestica, koje se razlikuju u količini i/ili sastavu materijala koji modificira oslobađanje.
The method of claim 25, wherein therapeutically effective amount of crenolanib or a salt thereof is provided as a single agent or in combination with another pharmaceutical agent in a newly diagnosed hematologic malignant neoplastic disorder pediatric patient, to maintain remission, or a relapsed/refractory hematologic malignant neoplastic disorder pediatric patient. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove soli osigurana kao jedini agens ili u kombinaciji s drugim farmaceutskim agensom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije ili subjektu s relapsiranom ili refraktornom akutnom mijeloičnom leukemijom (AML).
A dosage form according to claim 1, wherein the active ingredient (A) is at least one active ingredient selected from the group consisting of opiates, opioids, tranquillisers, stimulants, barbiturates and further narcotics. 
Oblik davanja lijeka prema jednom od patentnih zahtjeva 1 do 8, naznačen time, da je djelatna tvar (A) barem jedna tvar izabrana iz skupine koja obuhvaća opioide, trankvilizante, stimulanse, barbiturate i daljnja opojna sredstva.
A method of treating cancer and/or inhibiting angiogenesis comprising administering the composition of claim 1 to a subject in need thereof, wherein the cancer to be treated is one or more selected from the group consisting of bladder, breast, brain, head and neck, liver, biliary tract, carcinomas, acute and chronic lymphoid leukemias, acute and chronic myelogenous leukemias, chronic myelomonocytic leukemias colorectal, gastric, gastrointestinal stromal, glioma, lymphomas, melanomas, multiple myeloma, myeloproliferative diseases, neuroendocrine, lung, pancreatic, prostate, renal cell, sarcomas, and thyroid cancers. 
Uporaba prema patentnom zahtjevu 13, naznačena time, da maligni tumor koji treba liječiti jest jedan ili više odabranih iz skupine koja se sastoji od malignih tumora mokraćnog mjehura, dojke, mozga, glave i vrata, jetara, bilijamog stabla, karcinoma, akutne i kronične limfatične leukemije, akutne i kronične mijeloične leukemije, kronične mijelomonocitne leukemije, malignog tumora kolorektuma, želuca, gastrointestinalnog stromalnog tumora, glioma, limfoma, melanoma, multipli mijeloma, mijeloproliferativnih bolesti, neuroendokrinog tumora, malignog tumora pluća, gušterače, prostate, bubrega, sarkoma i karcinoma štitnjače.
converting a compound of formula [48] to a compound of formula [49] wherein R1 and R6 are defined above; 
N ume, gdje su R! i R* definirani gore; (6) prevođenju spoja formule [48] u spoj formule [49]
In another preferred embodiment, following the addition of said 2-((1-methylpropyl)amino)ethanol, the suspension conductivity does not change by more than 10%, preferably does not change by more than 6%, and more preferably does not change by more than 3%. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da se nakon dodavanja navedenog 2-((1-metilpropil)amino)etanola, promjena vodljivosti otopine ne mijenja za više od 10 %, poželjno se ne mijenja za više od 6 %, poželjnije se ne mijenja za više od 3 %.
A preferred embodiment of the invention is represented by those compositions which comprise as component A) a compound of formula (I), wherein R1 is trifluoromethyl. 
PATENTNI ZAHTJEVI Pripravak koja je pogodan za kontrolu bolesti koje uzrokuju fitopatogeni, naznačen time što sadrži (A) spoj formule (I)
The gun stock according to claim 4, characterized in that said cheek rest structure comprises hooks formed on the sides of said cheek rest structure and adapted to engage respective lateral seats formed on the lateral edges of said open region of the main body. 
Kundak u skladu s patentnim zahtjevom 4, naznačen time što navedena struktura naslona za obraz sadrži kuke (10), načinjene na stranama navedene strukture naslona za obraz i prilagođene za međudjelovanje s odgovarajućim bočnim sjedištima (13), načinjenim na bočnim rubovima navedenog otvorenog područja glavnog tijela.
and R6′ are taken together with the carbon atoms to which they are bound to form: 
R* i R" se uzima zajedno s atomima ugljika na koje su vezani kako bi tvorili:
loop of the plate 14 stepper feeder 
- plastičnu deformaciju ploče;
The method as defined in claim 9, wherein: the vacuum pump draws off so much gas from the electrolysis chamber that, during operation of the electrolysis chamber, at most a quarter of the electrolysis chamber is filled with gas. 
Postupak sukladno zahtjevu 9 ili 10, naznačen time, da vakuumska pumpa (25) izvlači toliko plina iz komora za elektrolizu (20) da tijekom rada komore za elektrolizu (20), najviše se četvrtina komore za elektrolizu (20) napuni plinom.